Haplotype analysis of CYP11A1 identifies promoter variants associated with breast cancer risk

Cancer Res. 2007 Jun 15;67(12):5673-82. doi: 10.1158/0008-5472.CAN-07-0467.

Abstract

The CYP11A1 gene encodes the cholesterol side chain cleavage enzyme that catalyzes the initial and rate-limiting step of steroidogenesis. A large number of epidemiologic studies have implicated the duration and degree of endogenous estrogen exposure in the development of breast cancer in women. Here, we conduct a systematic investigation of the role of genetic variation of the CYP11A1 gene in breast cancer risk in a study of 1193 breast cancer cases and 1310 matched controls from the Shanghai Breast Cancer Study. We characterize the genetic architecture of the CYP11A1 gene in a Chinese study population. We then genotype tagging polymorphisms to capture common variation at the locus for tests of association. Variants designating a haplotype encompassing the gene promoter are significantly associated with both increased expression (P = 1.6e-6) and increased breast cancer risk: heterozygote age-adjusted odds ratio (OR), 1.51 [95% confidence interval (95% CI), 1.19-1.91]; homozygote age-adjusted OR, 2.94 (95% CI, 1.22-7.12), test for trend, P = 5.0e-5. Among genes controlling endogenous estrogen metabolism, CYP11A1 harbors common variants that may influence expression to significantly modify risk of breast cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Asian People
  • Breast Neoplasms / genetics*
  • Cholesterol Side-Chain Cleavage Enzyme / genetics*
  • Female
  • Gene Expression
  • Gene Expression Profiling
  • Genetic Predisposition to Disease*
  • Haplotypes*
  • Humans
  • Linkage Disequilibrium
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Genetic*
  • Promoter Regions, Genetic*
  • Risk Factors
  • Transcription, Genetic

Substances

  • Cholesterol Side-Chain Cleavage Enzyme